Iovance Biotherapeutics(US:IOVA)2020-11-11 00:02Company Overview - Iovance Biotherapeutics is a leading cell therapy company focused on the treatment of solid tumors[8] - The company's TIL therapy leverages and enhances the body's natural defense against cancer using a patient's own Tumor Infiltrating Lymphocytes[9] - Iovance has broad, company-owned IP around TIL therapy, including 20 granted or allowed U S patents for compositions and methods of treatment in a broad range of cancers relating to Gen 2 manufacturing process[11] Melanoma Program (Lifileucel) - In Cohort 2 of the C-144-01 trial, the objective response rate (ORR) was 364% (24/66) in heavily pretreated metastatic melanoma patients[26] - The disease control rate (DCR) in Cohort 2 was 803% (53/66)[21] - In metastatic melanoma, an estimated 7,230 U S patient deaths occur each year[17] Cervical Cancer Program (Lifileucel) - In the pivotal Phase 2 trial (C-145-04) for cervical cancer, the objective response rate (ORR) was 44% (12/27)[33] - The complete response (CR) rate in the cervical cancer trial was 11% (3/27)[33] - The disease control rate (DCR) in the cervical cancer trial was 85% (23/27)[33] Financial Position - As of September 30, 2020, the company had $7197 million in cash, cash equivalents, short-term investments, and restricted cash[48] - The company has an anticipated year-end cash balance of $7197 million[48] Manufacturing and Facilities - Iovance is building a 136,000 sq ft manufacturing facility in Philadelphia[8, 14] - The company's Gen 2 manufacturing process has a >90% success rate[3, 8]